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Summary 
Four monoclonal antibodies (mAbs) were produced binding to four nonoverlapping epitopes 
on the superantigen staphylococcal  enterotoxin B (SEB). The mAbs were tested for their ability 
to detect SEB bound to major histocompatibility complex (MHC) class II, to inhibit SEB binding 
to MHC class II, to inhibit SEB stimulation of T cell hybridomas, to bind to various nonfunctional 
mutants of SEB, and to capture and present SEB and its mutants to T  cells in the absence of 
MHC class II. We concluded that two mAbs, B344 and B327, bound to epitopes not required 
for superantigen function, one mAb, 2B33, blocked an MHC interaction site on SEB, and the 
fourth mAb, B87, blocked the T cell recognition site on SEB. Moreover,  two mAbs (B344 and 
2B33) were capable of presenting SEB, although much less efficiently than APC, to CD4- but 
not CD4 § T  cell hybridomas. The results confirm the functional domains on SEB originally 
defined by mutation and show that MHC class II is not always an essential component of the 
superantigen ligand. 
S 
taphylococcus aureus produces a set  of exotoxin superan- 
tigens that cause food poisoning and toxic shock in man 
and rapid weight loss in mice sometimes leading to death 
(1-5).  As superantigens these proteins bind to MHC class 
II molecules and activate a large set ofT cells in a V/3-specific 
fashion (6-12). This T cell stimulation and the accompanying 
massive release of lymphokines appear  to play an essential 
role in the toxicity of these proteins (13, 14). 
Although the amino acid sequences of the staphylococcal 
toxins are related, each has a unique V~ specificity. For ex- 
ample, in mice staphylococcal enterotoxin B (SEB) 1 stimu- 
lates T cells bearing V~7, 8.1, 8.2, and 8.3 (6, 10, 11), whereas 
SEA stimulates T cells bearing V/31, 3, 11, and 17a (10). We 
have identified mutants of SEB impaired either for binding 
to MHC or for interaction with ol/3 TCR-VBs (14). These 
mutations in SEB also eliminated in vivo toxicity in mice. 
When mapped on the structure of SEB, these mutations in- 
dicated different sites on the SEB surface for orb TCR versus 
MHC interaction (15). 
In the current study we have confirmed these conclusions 
using a set of four anti-SEB mAbs specific for four nonover- 
i Abbreviations used in this paper: CTM, complete tissue culture medium; 
FBS, fetal bovine serum;  SEB, staphylococcal enterotoxin B;  F-SEB, 
fluoresceinated SEB. 
lapping epitopes on SEB. Two of these antibodies define an 
MHC and an c~/3 TCR-interaction site on SEB, whereas, the 
other two react with sites not involved in SEB superantigen 
activity. Moreover, we found that two of these mAbs could 
substitute for MHC class II in presentation of SEB to T cell 
hybridomas. 
Materials and Methods 
Cell Lines.  Three T cell hybridomas  were used in these studies, 
all derived from B10.BR mice. KS-6.1 (VB8.2+)  and KS-47.1 
(V/~8.3+) both respond strongly to SEB presented by a variety of 
class II MHC molecules (6, 14). KSEA-1 (V/~I+) responds to SEA 
presented by a variety of class II MHC molecules (16). The HLA- 
DR1  homozygous lymphoblastoid line, LG2, was used as the 
antigen-presenting cell line for SEB and SEA (14, 17). 
Toxins.  SEA was obtained from Toxin Technology (Madison, 
WI). Recombinant  wild type and mutant SEBs were affinity  purified 
from lysates  of Escherichia coli as previously  described (14). Fluorescei- 
nated SEB (F-SEB) was produced using fluorescein  isothiocyanate 
by standard techniques. 
IL.2 Assays.  Stimulations ofT cell hybridomas to produce Ib2 
were done in 96-well microtiter plates as previously described (18) 
using 5  x  104 hybridoma cells, 5  x  10  ~ 1./32 APC cells and var- 
ious concentrations of SEB. Ib2 production was measured using 
the MTT assay (19). 
Mice.  B10.Q/3BR mice (20) were bred in the animal care fa- 
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tory Medicine. 
B CellHybridomas and mAbs.  B cell hybridomas secreting mAbs 
specific for SEB were produced by fusion of the hybridoma cell 
line SP2/0 (American Type Culture Collection,  Kockville, MD) 
to spleen cells from SEB immunized B10.OflBR mice. The mice 
were immunized first subcutaneously with  50/xg  SEB in CFA, 
then boosted intraperitoneally at biweekly intervals twice with 50 
#g of SEB in IFA.  After several months rest a final boost with 
100 #g i.p.  of SEB in saline was given 3 d before sacrifice. Anti- 
SEB-secreting hybridomas were identified by ELISA and cloned 
at limiting dilution, mAbs were typed with isotype-specific reagents 
(Fisher Scientific,  Pittsburgh,  PA) and purified from ascites fluid 
or culture supernatants using protein A (for 3"2b) or protein G (for 
3,1) (Sigma Chemical Co., St. Louis, MO). Purified antibodies were 
biotiuyhted using N-hydroxylsuccinylbiotin (Sigma Chemical Co.). 
Affinity Measurements.  The affinities  of anti-SEB mAbs were 
determined  using a BIAcore (Biosensor;  Pharmacia,  San Diego, 
CA). Each mAb was coupled to the support of a single channel 
of the instrument to a level of ,,~20,000  RU using carbodiimide 
and n-hydroxysuccinimide. On and off rates were measured at a 
flow rate of 5/~1 per min using SEB in the range of 25 to 400 nM 
in a buffer of phosphate saline.  5 #1 of glycine buffer (100 riM), 
pH 2.7, was used to regenerate the antibody between measurements. 
ELISA.  Wells ofmicrotiter plates were coated with one of the 
anti-SEB mAbs (10 #g/ml), washed, and blocked with fetal bovine 
serum (FBS).  They were then loaded with excess SEB. The cap- 
tured SEB was detected using biotinylated forms of other anti-SEB 
mAb, alkaline phosphatase-coupled avidin (Fisher Scientific),  and 
p-nitrophenylphopshate as substrate. Optical density of the wells 
was read at 405 nm using an automated plate reader (BIO-TEK 
Instruments Inc., Winooski,  VT). 
Toxin Binding to DR1 Class II MHC.  Binding of toxin to DK1 
class II molecules on LG2 was measured using two fluorescence 
assays.  In  the  first,  3  x  10  ~ LG2  cells  were  incubated  with 
different concentrations of F-SEB at 37~  for 2 h in balanced salt 
solution containing 0.1% Na azide.  The cells were washed thor- 
oughly and the extent of F-SEB binding assessed using an Epics 
C  flow cytometer (Coulter  Corp.,  Hialeah,  FL).  In the  second 
assay, LG2 cells  were incubated  with  various concentrations  of 
nonfluoresceinated  SEB, washed, then incubated with excess of each 
of the anti-SEB mAbs, washed again, then incubated with fluorescei- 
nated goat antibody to the appropriate mouse heavy chain class 
(Fisher Scientific), and washed again. Finally the cell-bound fluores- 
cence was analyzed as above. 
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nonoverlapping epitopes on SEB. The biotinylated version of each mAb 
was used to detect SEB captured with the unconjugated forms of the four 
mAbs. Wells of Immulon  |  three-microtiter plates (Dynatech Labs., Inc., 
Chantilly, VA) were coated overnight with 100/zl of each mAb (10/~g/ml 
PBS) and blocked with 25% FBS in PBS. SEB (6/zg/ml PBS) was added 
at 100/~l/well for 2 h at room temperature, then after extensive washing, 
100 #1 of the biotinylated form of each mAb (20/zg/ml) was added to 
a specific set of wells. The bound biotinylated mAbs were detected using 
Extravidin-alkaline phosphatase andp-nitrophenyl phosphate as substrate. 
OD of the wells was read at 405 nm using Microphte Autoreader. 
in the functional differences among the mAbs, especially the 
3'1 mAbs. 
B87 and 21333 Inhibit  T  Cell Hybridoma Response to SEB, 
The four mAbs were tested for their ability to inhibit  the 
response of the mouse VflS.2+  T  cell hybridoma,  KS-6.1, 
to a limiting dose of SEB presented by the DR1 §  cell line, 
Table  1.  Kinetics and Affinity Measurements 
of the mAbs for SEB 
mAb  k,,,  kdi,,  KD 
Results 
Identification  of Four mAbs Specific for Different Epitopes on 
SER  After preliminary characterization of 10 anti-SEB mAbs 
produced from B10.OflBR mice, four: B334 (3'1), B327 (3'2b), 
B87 ('/1), and 21333 (3,1), were chosen for these experiments. 
Using a capture ELISA we attempted to detect SEB captured 
by each of the mAbs with biotinylated forms of the mAbs 
(Fig. 1). In each case all of the biotinylated mAbs bound well 
except the one that had been used to capture the SEB indi- 
cating that each mAb bound to an independent nonoverlap- 
ping epitope on SEB.  Using the BIAcore we estimated the 
affinity of each mAb for SEB (Table 1). The three 3'1 mAbs 
had similar affinities of 5-10 nM,  while the -/2b mAb had 
a somewhat lower affinity of ,-100 nM. Thus in the subse- 
quent experiments differences in affinities played a minor role 
moI- t s- t  sec- i 
B344  (3"1)  1.8  ￿  10  s  1.0  ￿  10 -3  6.0  ￿  10 -9 
B87  (3,1)  5.5  ￿  104  5.2  x  10 -4  9.3  x  10 -9 
2B33  (T1)  3.9  x  10  s  2.0  x  10 -3  5.2  x  10 -9 
B327  (3/2b)  3.9  ￿  104  3.7  x  10 -3  9.5  x  10 -s 
Isotypes  of the mAbs were determined using an ELISA. Wells of Immulon  | 
3 microtiter plates were coated overnight with different mAbs. Isotype- 
specific secondary reagents coupled to alkaline phosphatase were used to 
determine the isotype of tested mAbs. Affinity of the mAbs for SEB were 
measured using the BIAcore  machine (Biosensor; Pharmacia). About 20,000 
R.U of each mAb was immobilized onto a sensor chip, then different con- 
centrations of SEB were used to measure association and dissociation rates 
for each mAb. Glycine buffet (100 mM), pH 2.7, was used to regenerate 
mAbs between measurements. 
616  Defining the Functional Domains of Staphylococcal Enterotoxin B 10000 
~  100t). 
"~  100 
I0 
B327 
~-..~----~-.r.._  . 
",.  "Q  2B33  k ...... ":("  .... 
\  ". 
\  Q'.. 
"% ................  ii~ 
.......  i  .......  ,  ........  J  ........ 
0.1  1  I0  100 
mAb  [nMl 
(a)  (h) 
1-ib 
1000-~ 
~d 
100- 
10- 
B~44  B327 
B87  2B33 
0.1  1  10  100 
mAb  [nM] 
Figure  2.  B87 and 2B33 mAbs 
inhibit  the  response of  KS-6.1 
(V/$8.2) T cell hybridoma to SEB. 
The mAbs were tested for their ca- 
pacity to inhibit the response  of KS- 
6.1  (VBS.2) T  cell hybridoma to 
SEB (a) or the response of KSEA-1 
(VB1) T cell hybridoma to SEA (b), 
in both cases the toxin was presented 
by (DR1 +) LG2 cells. Various con- 
centrations of each mAb were in- 
cubated overnight at 37~  with 5 
x  104Tcellsand5  x  104LG2 
cells in the presence of a limiting 
dose  of  toxin  (71.4 nM).  II-2 
production by was measured as de- 
scribed  in  the  Materials  and 
Methods. 
LG2 (Fig. 2 a). The response of the V~l § T  cell hybridoma, 
KSEA-1,  to SEA was used as a negative control (Fig.  2  b). 
Dose-dependent inhibition of the response to SEB was seen 
with both mAb B87 and  2B33.  Little inhibition  was seen 
with mAb B344 or B327. None of these antibodies inhibited 
the response of KSEA-1 to SEA, indicating that the inhibi- 
tion  was  specific for SEB. 
Correlation of  mAb 2B33 and DRl-biruting Site on SEE,  Since 
binding of toxin to MHC class II molecules is a prerequisite 
for presentation by LG2 to the T cell hybridomas (6, 21-23), 
it is possible that B87 and 2B33 mAbs could have blocked 
the T  cell hybridoma response either by blocking binding 
of SEB  to MHC  or by blocking  T  cell recognition  of the 
toxin/MHC  complex.  To distinguish  these possibilities we 
tested the ability of the mAbs either to interfere directly with 
SEB binding to MHC class II or to detect SEB already bound 
to MHC class II. In the first case we preincubated a limiting 
amount of F-SEB with various concentrations of each mAb 
and then tested the ability of the complex to bind to DR1 
on LG2 cells. The results (Fig. 3) show that mAb 2B33 was 
able to block F-SEB binding to LG2, whereas the other three 
mAbs could not. Interestingly, mAbs B344 and B87, instead 
of inhibiting,  produced  enhanced  F-SEB binding,  whereas 
B327 had no effect at all.  This may have something  to do 
with an increased avidity of the F-SEB for LG2 after dimer- 
ization with either B344 or B87. The failure ofB327 to show 
this effect may have been because the location of this epitope 
on the SEB molecule led to a geometry of the complex which 
precluded  bivalent binding  (see below). 
In the second experiment the LG2 cells were preincubated 
with a high concentration  of SEB.  The unbound  SEB was 
washed away and an attempt was made to detect the bound 
SEB with  each mAb in conjunction  with a fluoresceinated 
secondary reagent (Fig. 4). Both B344 and B87, but neither 
2]]33 or B327, detected SEB after it was compkxed with DR1. 
Taken together the results thus far suggested that the epi- 
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tope detected by 2B33 coincided with an MHC-interaction 
site on SEB and that the B87 epitope was a good candidate 
for a TCK-interaction site. The B344 epitope was apparently 
at some distance from any functional site on the toxin. The 
B327 epitope was apparently close enough to an MHC  in- 
teraction  site to be blocked after binding  of SEB  to DR1, 
but  itself did  not  appear to define  a  functional  site. 
Functional Mutations in SEB Affecting  the Binding of mAb 
2B33 andB87.  In a previous study we identified amino acids 
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Figure  3.  Inhibition of binding of SEB to DR1 expressed on the sur- 
face of LG2 cells. (a) Various concentrations of F-SEB were incubated with 
3  x  l0  s LG2 cells for 2 h at 37"C. Excess SEB was washed away from 
the LG2 cells and the cells were then analyzed for surface fluorescence on 
an Epics C flow cytometer (Coulter Corp.). Position of the arrow indi- 
cates the SEB dose used in the next inhibition experiment. (b) Various 
concentrations of each mAb were incubated with a limiting dose of F-SEB 
(as indicated in Hg. 2 a) in complete tissue culture medium (CTM) for 
1 h at 37~  After the first incubation, 3  x  105 LG2 cells were added 
to each well for 2 h at 370C. The calls were then washed 4 x and analyzed 
for surface fluorescence. i0 
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Figure 4.  Detection of DKl-bound SEB by B344 and B87 mAbs. SEB 
(50 pmole) was incubated with 3  ￿  105 LG2 cells in 100 #l of CTM at 
37~  for 2 h.  After thorough washing, various concentrations  of each 
mAb were added to the cell suspension for 1 h at 37~  The cells were 
washed 4x  and incubated again for 15 rain at 4~  with fluorescinated 
goat anti-mouse "yl or 3r2b secondary reagents (Fisher Scientific). The 
cells were washed thoroughly and then analyzed for surface fluorescence 
with an Epics C  flow cytometer. 
in SEB important in either MHC binding or T cell recogni- 
tion (14). Mutations in these amino acids diminished either 
the ability of SEB to bind to MHC class II or the ability 
of MHC bound SEB to stimulate T  cells. To confirm our 
characterization of the anti-SEB mAbs were tested their ability 
to bind to SEB carrying either of these types of functional 
mutations. 
Since we had previously shown that the binding of mAb 
B344 was unaffected by any of the SEB mutations we had 
produced (14), we used B344 to capture wild-type SEB or 
any of a number of mutant SEBs. The ability of the captured 
toxin to bind B327, 2B33, or B87 was tested with biotinylated 
forms of the mAbs in an ELISA (Fig. 5). None of the muta- 
tions tested altered the ability of B327 to bind to SEB. On 
the other hand the binding of B87 was affected by mutations 
in N23.  Mutations in this amino acid have minimal effect 
on SEB binding to MHC, but nearly eliminate T cell stimu- 
lation (14). Likewise, the binding of 2B33 was reduced by 
a number of the mutations in amino acids in the region of 
amino acids 44-48. Most dramatic was the mutation D48>G. 
Smaller effects were seen with some of the mutations in F44. 
These mutations all reduce the ability of SEB to bind to MHC 
by ~,l,000-fold (14). Mutations in 60N or 61Y, which also 
form part of the TCR-interaction site, had no effect on the 
binding of any of the mAbs. These results mapped the 2B33 
epitope as overlapping, but not identical, with the MHC- 
binding site including amino acids 44-48 and the B87 epi- 
tope as including N23. 
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Figure 5.  Functional mutations in SEB affecting the binding of 2B33 
and B87 mAbs. The capacity of the mAbs to bind SEB mutants is tested 
using a capture ELISA as described in Fig. 1. All mutants were captured 
with B344 and detected with biotinylated forms of B87, 2B33, and B327 
mAbs, respectively. SEB mutants along with their residues that have been 
changed are illustrated at the bottom of the figure. The functional site 
affected (MHC or TCK) by specific  residue(s) substitution is shown directly 
below the residue(s) at the bottom right of the figure. 
Anti-SEB Substitutes for MHC Class II in Presenting SEB 
to T Cells.  A recent report indicated that toxin superantigens 
could stimulate T cells in the absence of MHC class II when 
made polyvalent by capturing with antibody on a solid sup- 
port (24). Therefore, in a final set of experiments we tested 
the ability of the mAbs to substitute  for MHC class II in 
presenting SEB. In preliminary experiments, we screened a 
panel of SEB-reactive T cell hybridomas for response to SEB 
captured by the immobilized mAbs.  All the tested T  cdl 
hybridomas  that were CD4-,  but not those which were 
CD4 +, responded (data not shown). We have subsequently 
confirmed that CD4 inhibits recognition of SEB presented 
by antibody, but not by MHC dass II, although the exact 
mechanism is not yet clear (Hamad, A. K. A., P. Marrack, 
and J. W. Kappler, manuscript in preparation).  Therefore, 
the CD4-  hybridoma, KS47.1, was used in the following 
experiments. Microtiter plate wells were coated at 100 #g/ml 
with each of the mAbs in order to saturate the surface. After 
blocking with FBS, various concentrations of  SEB were added 
along with the T cell hybridoma. As controls in paralld cul- 
tures SEB was presented by DK1 § LG2 cells. Virtually no 
response was seen with SEB presented by B87 or B327 (Fig. 
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Figure 6.  Presentation of SEB to the KS-47.1 (Vf18.3) T cell hybridoma 
by B344 and 2B33 mAbs. Wells of Immunolon  |  3 microtiter plates were 
coated with 100 #1 of each mAb (666.6 nM) overnight  at 4~  Excess 
mAbs were washed away and various concentrations of SEB were added 
at 100/~l/well  overnight at 4~  After a single wash, 5  x  104 KS-47.1 
cells were added to each well in CTM. In a parallel set of positive controls 
wells, LG2 cells were used as an APC. After a 24-h incubation, the amount 
of IL-2 produced by the T cells was measured. 
6). Strong responses were seen with SEB presented by 2B33 
or B344, although ,o 10-80 times as much SEB was required 
as with the DR1 bearing antigen-presenting cells. These results 
indicated that although DR1 was the most efficient in pre- 
senting SEB, class II MHC was not absolutely required for 
presentation provided that SEB was presented in the proper 
orientation in a multivalent form. The failure of B87 to present 
SEB was predicted since this antibody blocks the SEB or3 
TCR-interaction  site.  The failure of B327 to present  SEB 
could have been due to its lower affinity or again to the inap- 
propriate  geometry of its complex with  SEB. 
As discussed above, our previous studies established the 
region around F44-D48 in SEB as important in MHC class 
II binding,  but since this binding  was a prerequisite for T 
cell recognition,  we could not formally exclude that  these 
mutations had an effect on the T cell-interaction site of SEB 
as well. The finding that mAbs could replace MHC in pre- 
sentation allowed us to test this point  in a second experi- 
ment.  We predicted that we should recover T  cell stimula- 
tion  with  these  mutants  if they  are  presented  with  the 
appropriate mAb rather than with MHC class II. We used 
the mAbs B344 and 2B33 to present SEB or BR358 (F44>S, 
which did not effect 2B33 binding [Fig.  5]) to the V38.3 + 
T  cell hybridoma,  again comparing the responses to those 
obtained with LG2. The c~3 TCR-interaction mutant BC88 
(N23>K)  was used as a negative control,  since its pheno- 
type should be independent of the presenting molecule. Again 
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Figure 7.  Wild type and mutants of SEB induce comparable T cell re- 
sponses when presented by B344 or 2B33 mAbs. SEB and selected mu- 
tants were used to stimulate KS-47.1 T cell hybridoma as in Fig. 6. In 
a B344 mAb was used whereas in b 2B33 mAb was used to present SEB 
and its mutants. 
wild-type SEB was presented by both LG2 and the mAbs, 
although  the cells were ,o10-80 times more efficient than 
the mAb (Fig. 7, a and b). As expected, BC88 bearing a mu- 
tation in the ot/~ TCR-interaction amino acid, N23, was not 
presented by either  LG2  or  the  mAbs.  As we previously 
showed, BR358 was 1,000 times less effective than wild-type 
SEB when presented by LG2, consistent with its poor MHC- 
binding properties. However, BR358 was indistinguishable 
from wild-type SEB when presented by the mAbs (Fig.  7, 
a and b). Similar results were obtained with a number of other 
mutants in the F44-D48 region using B344 as the presenting 
antibody (data not  shown).  These results confirm the im- 
portance of N23 in T cell recognition and show that muta- 
tions in the region around F44, drastically diminish the ability 
of MHC class  II-bearing cell to present  SEB but have  no 
effect on ot/~ TCR interaction. 
Discussion 
In this study four mAbs were analyzed, each of which rec- 
ognized a different, nonoverlapping epitope on SEB. Two of 
these mAbs, B344 and B327, bound to epitopes apparently 
not involved in the superantigen  activity of SEB. We con- 
cluded that  the epitope bound by the third mAb, B87, in- 
cluded an essential part of the or/3 TCR-interaction  site on 
619  Hamad et al. Figure  8.  Locations  of the epitopes on SEB that are recognized  by the 
mAbs. A schematic  diagram of the SEB backbone  is shown taken from 
Swaminathan  et al. (15). Amino  acids are shown  mutations  in which  effect 
both mAbs binding and superantigen  function.  The predicted  approxi- 
mate  locations  of the epitopes  for 2B33 and B87 are shown. The locations 
of the epitopes for B344 and B327 are not known. 
SEB based on the antibody's: (a) inhibition of T cell stimula- 
tion by SEB; (b) failure to inhibit SEB binding to MHC class 
II; (c) ability to detect SEB already bound to MHC class II; 
(d) reduced binding to SEB-bearing  mutations in the oe/3 
TCR-interaction amino acid, N23; and (e) inability to present 
SEB or its mutants for T cell recognition. We concluded that 
the epitope bound by the fourth mAb, 2B33, overlapped  an 
essential MHC-interaction site on SEB based on the antibody's: 
(a) inhibition of T  cell  stimulation by SEB; (b) inhibition 
of SEB binding to MHC class II; (c) failure  to detect SEB 
already bound to MHC class II; (d) reduced binding to SEB 
bearing a number of mutations in the MHC-interacting F44- 
D48 region;  and (e) ability to present SEB (or those F44- 
D48 mutants to which it bound) for T cell recognition. The 
relevant portions of the SEB molecule are shown schemati- 
cally in Fig.  8. 
The role of MHC class II in superantigen presentation has 
been a puzzle. Initial experiments appeared to show that MHC 
class II presentation was essential for ol/3 TCR recognition 
of toxin superantigens suggesting that some portion of the 
MHC may form an important part  of the ligand or that 
binding to MHC induces a conformational change in the toxin 
molecule.  This  view  was  supported  by  the  inability  of 
nonspecifically immobilized toxins to stimulate T cells. How- 
ever, thus far no essential c~3 TCR/MHC-interaction amino 
acids have been identified, since most differences in toxin pre- 
sentation due to allelic, isotypic, or even xenogeneic differ- 
ences in MHC class II molecules can be attributed to toxin/ 
MHC,  rather  than  or/3 TCR/MHC  interactions.  These 
findings suggest an alternative view that a large part of the 
role of MHC class II may be to form a polyvalent ligand 
by capturing the toxin superantigen in a specific orientation 
for oe3 TCR recognition. This view has received support from 
several reports of either polyspecific antibodies or other non- 
MHC class II cellular receptors  capable of binding and pre- 
senting superantigen toxins to T  cells  (24,  25). 
Our findings here support this latter view. SEB captured 
by immobilized forms of two of the four anti-SEB  mAbs 
stimulated the T cell hybridoma used in these studies. These 
results  show that an MHC class II molecule is not an abso- 
lutely essential part of the SEB ligand for c~3 TCRs, but that 
orientation of the SEB is important, since presentation does 
not occur with an antibody that interferes with the T  cell 
interaction site on the toxin. However, the efficiency of the 
presentation was 10-80 times less than that seen with a MHC 
class II antigen-presenting cell. This could indicate some re- 
sidual role for or/3 TCR/MHC interactions, but could also 
be due to the differences between a completely immobilized 
ligand versus  one free to move about in a membrane. We 
have recently produced soluble forms of MHC class II mole- 
cules  which should allow us to address  this question. 
Finally antibody titers have been correlated with resistance 
to the in vivo toxin effects of these bacterial superantigens, 
although the mechanism is not known (4).  This matched 
set of anti-SEB mAbs with similar affinities should help dis- 
criminate among protective mechanisms involving specific 
blocking of ee3  TCR or MHC interaction versus  simple 
antibody-mediated rapid clearance  of the toxins. 
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